Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy TYRA?
Source: PRnewswire
Clinical Progress: Tyra Biosciences has dosed its first patient in the SURF302 study for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) and is advancing its other clinical studies, including BEACH301 for pediatric achondroplasia and SURF431 for advanced hepatocellular carcinoma.
Financial Overview: As of June 30, 2025, Tyra reported cash and marketable securities totaling $296.3 million, which is expected to fund operations through at least 2027, despite a net loss of $28.1 million in the second quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TYRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TYRA
Wall Street analysts forecast TYRA stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.190
Low
30.00
Averages
33.75
High
37.00
Current: 29.190
Low
30.00
Averages
33.75
High
37.00
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Tyra Biosciences Director Sells 246,871 Shares for $5 Million
- Insider Transaction: On November 21, Tyra Biosciences Director Robert J. More sold 246,871 shares at $20.25 each for a total of $5 million, indicating confidence in the company's future despite being part of a Rule 10b5-1 trading plan.
- Shareholding Status: Post-transaction, More retains 3,833,425 shares valued at approximately $77.6 million at current prices, reflecting his ongoing belief in the company's long-term prospects.
- Market Performance: As of December 23, Tyra's stock has surged over 80% year-to-date, significantly outperforming the S&P 500's 18.4% return, indicating strong market optimism regarding its growth potential.
- Financial Condition: Although the third-quarter report showed slight increases in R&D and SG&A expenses along with a higher net loss, analysts generally rate Tyra as a moderate buy, suggesting confidence in its future growth despite its early-stage status.
See More
Tyra Biosciences Director Sells 246,871 Shares, Retains $77.6 Million Stake
- Share Sale: On November 21, 2025, Tyra Biosciences Director Robert More sold 246,871 shares under a Rule 10b5-1 trading plan at $20.25 per share, yet retains nearly 4 million shares valued at approximately $77.6 million, indicating continued confidence in the company's prospects.
- Stock Performance: As of December 23, 2025, Tyra's stock has surged over 80% year-to-date, significantly outperforming the S&P 500's 18.4% return, reflecting optimistic market sentiment regarding its biotechnology potential.
- Financial Status: In its early November Q3 earnings report, Tyra disclosed slight increases in R&D and SG&A expenses along with a higher net loss, despite not generating any revenue, highlighting the inherent risks of its early-stage operations.
- Management Changes: The company announced in December the appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, aiming to strengthen its management team to support future business growth and strategic execution.
See More
Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades: Morgan Stanley upgraded Accenture Plc from Equal-Weight to Overweight, raising its price target from $271 to $320, while Cantor Fitzgerald upgraded Microchip Technology Inc from Neutral to Overweight with a target increase from $65 to $85.
Price Target Increases: Wedbush raised Tyra Biosciences Inc's target from $30 to $37, and Chardan Capital increased Palvella Therapeutics Inc's target from $110 to $174, both maintaining positive ratings.
Mixed Ratings: Baird cut Dentsply Sirona Inc's price target from $14 to $12 while maintaining a Neutral rating, contrasting with their upgrade of Tandem Diabetes Care Inc from Neutral to Outperform with a target increase from $18 to $30.
Other Notable Changes: Goldman Sachs upgraded Rockwell Automation Inc from Sell to Neutral, raising its target from $329 to $448, while Needham increased SI-Bone Inc's target from $24 to $27, maintaining a Buy rating.
See More
Tyra Biosciences Appoints New Executives to Advance FGFR Drug Development
- Executive Appointments: Tyra Biosciences has appointed Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, who will be pivotal in advancing oral dabogratinib through global Phase 2 trials for skeletal dysplasia and urologic cancers.
- Extensive Experience: Ashar brings over 25 years of pharmaceutical and biotechnology experience, having served as Chief Commercial Officer at SpringWorks Therapeutics where he successfully launched two rare oncology products, while Faulds has over 20 years in regulatory strategy, most recently as SVP of Global Regulatory Sciences at Blueprint Medicines.
- Clinical Development Plans: Oral dabogratinib, TYRA's lead precision medicine candidate, is currently undergoing global Phase 2 clinical trials targeting pediatric achondroplasia and intermediate-risk non-muscle invasive bladder cancer, with the FDA granting Orphan Drug and Rare Pediatric Disease designations.
- Strategic Implications: The executive appointments and clinical development initiatives signify Tyra's strategic positioning in FGFR biology, aiming to enhance patient quality of life through precision medicines that address significant unmet medical needs.
See More
Insider at Tyra Biosciences Sells Shares Valued at $2,108,067, Recent SEC Filing Reveals
Sale of Shares: Daniel Bensen, the Chief Operating Officer of Tyra Bioscience, sold 131,411 shares on November 13, 2025.
Impact on Portfolio: The sale may have implications for his personal portfolio and the company's stock performance.
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Tyra Biosciences Director Sells 246,871 Shares for $5 Million
- Insider Transaction: On November 21, Tyra Biosciences Director Robert J. More sold 246,871 shares at $20.25 each for a total of $5 million, indicating confidence in the company's future despite being part of a Rule 10b5-1 trading plan.
- Shareholding Status: Post-transaction, More retains 3,833,425 shares valued at approximately $77.6 million at current prices, reflecting his ongoing belief in the company's long-term prospects.
- Market Performance: As of December 23, Tyra's stock has surged over 80% year-to-date, significantly outperforming the S&P 500's 18.4% return, indicating strong market optimism regarding its growth potential.
- Financial Condition: Although the third-quarter report showed slight increases in R&D and SG&A expenses along with a higher net loss, analysts generally rate Tyra as a moderate buy, suggesting confidence in its future growth despite its early-stage status.
See More
Tyra Biosciences Director Sells 246,871 Shares, Retains $77.6 Million Stake
- Share Sale: On November 21, 2025, Tyra Biosciences Director Robert More sold 246,871 shares under a Rule 10b5-1 trading plan at $20.25 per share, yet retains nearly 4 million shares valued at approximately $77.6 million, indicating continued confidence in the company's prospects.
- Stock Performance: As of December 23, 2025, Tyra's stock has surged over 80% year-to-date, significantly outperforming the S&P 500's 18.4% return, reflecting optimistic market sentiment regarding its biotechnology potential.
- Financial Status: In its early November Q3 earnings report, Tyra disclosed slight increases in R&D and SG&A expenses along with a higher net loss, despite not generating any revenue, highlighting the inherent risks of its early-stage operations.
- Management Changes: The company announced in December the appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, aiming to strengthen its management team to support future business growth and strategic execution.
See More
Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades: Morgan Stanley upgraded Accenture Plc from Equal-Weight to Overweight, raising its price target from $271 to $320, while Cantor Fitzgerald upgraded Microchip Technology Inc from Neutral to Overweight with a target increase from $65 to $85.
Price Target Increases: Wedbush raised Tyra Biosciences Inc's target from $30 to $37, and Chardan Capital increased Palvella Therapeutics Inc's target from $110 to $174, both maintaining positive ratings.
Mixed Ratings: Baird cut Dentsply Sirona Inc's price target from $14 to $12 while maintaining a Neutral rating, contrasting with their upgrade of Tandem Diabetes Care Inc from Neutral to Outperform with a target increase from $18 to $30.
Other Notable Changes: Goldman Sachs upgraded Rockwell Automation Inc from Sell to Neutral, raising its target from $329 to $448, while Needham increased SI-Bone Inc's target from $24 to $27, maintaining a Buy rating.
See More
Tyra Biosciences Appoints New Executives to Advance FGFR Drug Development
- Executive Appointments: Tyra Biosciences has appointed Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, who will be pivotal in advancing oral dabogratinib through global Phase 2 trials for skeletal dysplasia and urologic cancers.
- Extensive Experience: Ashar brings over 25 years of pharmaceutical and biotechnology experience, having served as Chief Commercial Officer at SpringWorks Therapeutics where he successfully launched two rare oncology products, while Faulds has over 20 years in regulatory strategy, most recently as SVP of Global Regulatory Sciences at Blueprint Medicines.
- Clinical Development Plans: Oral dabogratinib, TYRA's lead precision medicine candidate, is currently undergoing global Phase 2 clinical trials targeting pediatric achondroplasia and intermediate-risk non-muscle invasive bladder cancer, with the FDA granting Orphan Drug and Rare Pediatric Disease designations.
- Strategic Implications: The executive appointments and clinical development initiatives signify Tyra's strategic positioning in FGFR biology, aiming to enhance patient quality of life through precision medicines that address significant unmet medical needs.
See More
Insider at Tyra Biosciences Sells Shares Valued at $2,108,067, Recent SEC Filing Reveals
Sale of Shares: Daniel Bensen, the Chief Operating Officer of Tyra Bioscience, sold 131,411 shares on November 13, 2025.
Impact on Portfolio: The sale may have implications for his personal portfolio and the company's stock performance.
See More
